Apheresis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

The Apheresis Market size is estimated at USD 3.52 billion in 2024, and is expected to reach USD 4.62 billion by 2029, growing at a CAGR of 5.63% during the forecast period (2024-2029).

The COVID-19 pandemic had a profound impact on the growth of the Apheresis market, due to the extensive application of plasma therapy to treat patients infected with COVID-19. According to the study published in the Journal of Clinical Apheresis in December 2021, the Lack of supplies, notably RBC units and apheresis kits, was one of the main problems with patient treatment in the apheresis facility during the COVID-19 pandemic. Due to "stay home" instructions and concern about SARS CoV2 infection, the number of blood donors drastically reduced. Thus the studied market was initially impacted by the pandemic. Moreover, there were no vaccines or drugs to treat COVID-19, and most doctors opted for convalescent plasma therapy in patients who were severely affected by COVID-19. In this treatment, the plasma extracted from the blood of cured patients by the plasmapheresis technique was transfused into the patient who underwent treatment. Thus, given the wide usage of apheresis units in treating COVID-19 patients and increasing product approvals by the United States Food and Drug Administration (FDA), the apheresis market marked a positive growth during the pandemic, however currently as the pandemic subsided, the market lost some traction, however it is expected to have a stable growth during the forecast period of the study.

The propelling factors for the growth of the apheresis market include the increasing burden of diseases, a rise in the demand for blood components and their associated safety, technological advancements in the development of new apheresis techniques, and an increase in the reimbursement policies and funding for apheresis procedures. For instance, in June 2022, through the NHS MedTech Funding Mandate (MTFM), NHS England in the United Kingdom has chosen the automated red blood cell exchange (RBCX) treatment carried out on the business's Spectra Optia Apheresis System to treat sickle cell disease. Due to this choice, Spectra Optia will be used more frequently in hospitals all around England. Patients with sickle cell illness will now have better access to this therapy. Thus, the increasing funding initiatives related to apheresis are propelling the market growth.

The use of apheresis in clinically ill patients is increasing day by day, and it has been widely used as the primary therapy or as an adjunct to other treatments for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure.

Along with these factors, the increasing product innovations and approvals have been driving the market growth. For instance, in July 2021, Terumo Blood and Cell Technologies announced a direct offering for physicians to perform extracorporeal photopheresis immunotherapy (ECP) procedures at the patient's bedside. The company has expanded the functionality of Spectra Optia. The UVA PIT System ECP can now be performed using these devices as a functionally closed, online, multistep system with mononuclear cell collection (MNC) and continuous mononuclear cell collection (CMNC) protocols.Thus, owing to the aforementioned factors, the apheresis market is expected to witness healthy growth over the forecast period. However, lack of skilled professionals, blood contamination and cost associated with apheresis procedures restrain the market growth.

Apheresis Market Trends

Hematological Disorders Segment is Expected to Witness Significant Growth During the Forecast Period

Hematologic disorders are the disorders of blood and blood-forming organs which include problems with red blood cells, white blood cells, platelets, bone marrow, lymph nodes, and spleen. Hematological disorders make a substantial contribution to the morbidity and mortality of individuals across the globe. As per the May 2022 update by the CDC, sickle cell disease (SCD) affects approximately 100,000 Americans. It occurs among about 1 out of every 365 Black or African American births. Early diagnosis and treatment are the best ways to protect the life of a patient with a blood cell disorder. Hence, owing to the increasing burden of hematological incidences and growing applications of apheresis as a treatment method for hematological disorders, the studied segment is expected to experience growth in the forecast period.

There has been a rise in therapeutic aphereses over the past few years; for instance, immunoadsorption, double filtration, and cytapheresis are readily used in the treatment of both primary and secondary autoimmune renal diseases. Additionally, as per ClinicalTrails.gov, as of November 2022, there are 51 studies reported on apheresis for hematological malignancy among which about 27 studies that were completed and 8 studies are currently recruiting for apheresis for different hematological disease development across the globe.

Furthermore, apheresis has a vital role in the management of sickle cell anemia disease. As per the study published in Sage Journal in November 2021, apheresis equipment was found to provide better management in red cell exchange therapeutic procedures being performed in sickle cell. Thus, owing to the aforementioned factors, the application of apheresis in treating various hematological disorders will ultimately drive the segment growth.

North America is Expected to Witness Healthy Growth Over the Forecast Period

North America is expected to grow over the forecast period due to the growing burden of various ailments related to blood, such as kidney diseases, metabolic diseases, cancer, and neurological disorders, the presence of established healthcare infrastructure, and high patient awareness levels. According to the Leukemia & Lymphoma Society (LLS) 2021, approximately every three minutes, one person in the United States is diagnosed with blood cancer. The new cases of leukemia, lymphoma, and myeloma accounted for 9.8% of the total 1,898,160 new cancer cases diagnosed in the United States in 2021. The high incidence of target diseases is driving the growth of the market studied.

The increasing reimbursement policies in the country for apheresis procedures and devices is increasing the demand for apheresis. In January 2022, United Healthcare Group issued a document UnitedHealthcare Commercial Medica Policy, the document provides a medical policy for apheresis procedures which are performed for multiple indications except for stem cell collection or harvesting for use in bone marrow/stem cell transplantation. These, available policies for the procedures are increasing demand for the procedures among the target population, which is ultimately driving the market for apheresis in the country.

Furthermore, the American Society for Apheresis (ASFA) declared September 21, 2021, to be Apheresis Awareness Day, and stated that it would take place every year on the third Tuesday in September moving forward. This was intended to recognize numerous donors, patients, and apheresis professionals who have dedicated their lives to saving others by employing evidence-based practice to promote apheresis medicine and raise awareness of apheresis medicine.Thus, these aforementioned factors are expected to significantly boost the apheresis market in North America over the forecast period.

Apheresis Industry Overview

The market studied is moderately competitive and dominated by a few major players. Currently, the market is well established in many areas and has shown nascent success. However, its full potential is yet to be determined in developing regions. With increasing government initiatives, awareness among people is also increasing, which is further driving the growth of the market studied. Additionally, strategic alliances and product launches by major companies are expected to drive market growth. Some of the major players in the market are B. Braun SE, Asahi Kasei Corporation, Fresenius SE & Co. KGAA and Terumo Corporation (Terumo BCT Inc.) among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support